Aducanumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Aducanumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
Targetbeta amyloid
Clinical data
Other namesBIIB037
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
KEGG
Chemical and physical data
FormulaC6472H10028N1740O2014S46
Molar mass145909 g·mol−1

Aducanumab is a human monoclonal antibody that has been studied for the treatment of Alzheimer's disease (AD).[1] It was developed by Biogen Inc., which licensed the drug candidate from Neurimmune, its discoverer.[2] The antibody targets aggregated forms of β-amyloid found in the brains of people with Alzheimer’s disease, in the hopes of reducing its buildup.[3] Biogen halted development of the drug in March 2019 after preliminary data from two phase III trials suggested it would not meet the primary endpoint.[4][5][6] On 22 October 2019 Biogen announced that it would be re-starting the FDA approval process for aducanumab stating that new analysis of a larger dataset showed that the drug reduced clinical decline in patients with early Alzheimer's disease when given at higher doses.[7] The reanalysis of the data from the discontinued trial concluded that patients receiving a high dose had a 23% reduction in their rate of decline.[8][9]

Research[edit]

Interim results from the second Phase 1 study of the drug were reported in March 2015.[1][10]

A phase 1b study was published in August 2016, based on one year of "monthly intravenous infusions" of aducanumab, with brain scans to measure amyloid plaques.[11] Phase 3 clinical trials were ongoing in September 2016,[11] but were canceled in March 2019 after "an independent group's analysis show[ed] that the trials were unlikely to 'meet their primary endpoint.'"[12]

Despite this, in October 2019 the company announced their intention to seek regulatory approval, following a reanalysis of the data.[13][14][15]

References[edit]

  1. ^ a b Fox C (April 28, 2015). "The Story of Biogen's Alzheimer's Drug, Aducanumab". Drug Discovery and Development. Archived from the original on 2015-07-01.
  2. ^ Zacks R (November 20, 2007). "Biogen Inks $380 Million Deal with Swiss Company". Xconomy.
  3. ^ Toyn J (May 2015). "What lessons can be learned from failed Alzheimer's disease trials?". Expert Review of Clinical Pharmacology. 8 (3): 267–9. doi:10.1586/17512433.2015.1034690. PMID 25860157.
  4. ^ Ducharme J (March 21, 2019). "Biogen Halts Promising Alzheimer's Drug Trials Due to Disappointing Results". Time. Retrieved 2019-03-21.
  5. ^ Li Y (March 21, 2019). "Biogen posts its the worst day in 14 years after ending trial for blockbuster Alzheimer's drug". CNBC.
  6. ^ Annett T. "Biogen Plunges More Than 25 Percent on Alzheimer's Setback". Bloomberg News.
  7. ^ Howard J, Gumbrecht J (October 23, 2019). "Drugmaker to seek approval for Alzheimer's treatment". CNN. Retrieved October 23, 2019.
  8. ^ Herper M (October 22, 2019). "In shocking reversal, Biogen to submit Alzheimer's drug for approval". STAT. Retrieved October 22, 2019.
  9. ^ "Biogen Plans Regulatory Filing for Aducanumab in Alzheimer's Disease Based on New Analysis of Larger Dataset from Phase 3 Studies". Biogen. October 22, 2019. Retrieved October 22, 2019.
  10. ^ Herper M (March 20, 2015). "Biogen Drug Could Inspire New Hope For Alzheimer's Treatments". Forbes.
  11. ^ a b Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, et al. (September 2016). "The antibody aducanumab reduces Aβ plaques in Alzheimer's disease". Nature. 537 (7618): 50–6. Bibcode:2016Natur.537...50S. doi:10.1038/nature19323. PMID 27582220.
  12. ^ Li Y (21 March 2019). "Biogen shares plunge nearly 30% after ending trial for Alzheimer's drug Aducanumab". CNBC.
  13. ^ Roberts M (22 October 2019). "First drug to slow Alzheimer's may be available soon". BBC News. Retrieved 22 October 2019.
  14. ^ Foster L (October 26, 2019). "Drug 'could be biggest Alzheimer's development'". BBC News. Retrieved October 26, 2019.
  15. ^ Kunkle F (December 6, 2019). "Biogen's potential new drug for Alzheimer's disease gets cautiously optimistic review following presentation". The Washington Post.